ACTION Registry GWTG Version 2.4



Similar documents
NCDR ACTION Registry - GWTG v2.4 Acute Coronary Treatment and Intervention Outcomes Network Registry

Mission: Lifeline North Texas STEMI Workshop. The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care

Implementing a Prehospital 12-Lead Program

ACTION Registry - GWTG: Defect Free Care for Acute Myocardial Infarction Specifications and Testing Overview

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

3/8/2014. Kevin Daniel RN, CEN Quality Improvement Northside Hospital System

STEMI Systems of Care

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Mission: Lifeline EMS Recognition Guide

Improving PCI Benchmark times in a Non-PCI World

How To Recognize An Ambulance Service For A Mission: Lifeline

There are 5 demographic data elements that include gender, date of birth, race, ethnicity status,

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

EMR Tutorial Acute Coronary Syndrome

Disclosures. The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted grants from:

Dallas Caruth Initiative Part 1 and Part 2 Raymond L. Fowler, MD, FACEP, DABEMS Dudley Wilcoxson, NREMT P Karen Pickard, RN

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

ACC/AHA Performance Measures

ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

Business Loan Insurance Plan Critical Illness Claim - Policy 57903

Developing a Dynamic Team Approach to Stroke Care. Emergency Medical Services 2015

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Rx Updates New Guidelines, New Medications What You Need to Know

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

convey the clinical quality measure's title, number, owner/developer and contact

NCDR ACTION Registry -GWTG v2.4 Coder's Data Dictionary

S Hutton, A Inglis, C McKiernan, S Hearns, P Campbell, M Lindsay

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Official Online ACLS Exam

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

FL PR Stroke Registry Goals

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

New Oral Anticoagulants. How safe are they outside the trials?

STEMI System of Care: Upland Hills Health A Transferring Non-PCI Facility. Estimated ground transport time: 54 minutes

Review of the Stroke and VTE Measure Sets

Anticoagulation Therapy Update

DVT/PE Management with Rivaroxaban (Xarelto)

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

STROKE PREVENTION IN ATRIAL FIBRILLATION

ALS INTERFACILITY TRANSFERS. SUPERSEDES: January 8, 2009

Medical Tourism - The Role of Intervals inCardiovascular Cancer

URN: Family name: Given name(s): Address:

Antiplatelet and Antithrombotics From clinical trials to guidelines

AnMed Health Disparities Dashboard

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Scelte Antitrombotiche nelle SCA delle UTIC Italiane: Nuovi Dati dal Registro EYESHOT

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Quality Improvement. Quantified. TM. Program Overview July, 2008

Heart Attack: What You Need to Know

Atrial Fibrillation Management Across the Spectrum of Illness

Rivaroxaban for acute coronary syndromes

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Management of Acute Coronary Syndrome / NSTEMI

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

American Heart Association (AHA) Mission: Lifeline ND A Year in Review. 2013, American Heart Association 1

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Critical Bleeding Reversal Protocol

AHA/ASA Ischemic Stroke Performance Measures

rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Dorset Cardiac Centre

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

NOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Overview of the TJC/CMS VTE Core Measures

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Intermedix Inc. EMR 2006 Data Element Name. Compliant. Data Number. Elements

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Addendum to Clinical Review for NDA

Chronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical

2015 Data Validation Strategy

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

Inpatient and Outpatient Manual Changes for 2015

The author has no disclosures

Level III Stroke Center Data Collection Requirements

Transcription:

ACTION Registry GWTG Version 2.4 Dr. Joanne Foody Kim Hustler The following relationships exist: Dr. Foody:Janssen, Sanofi, Genzyme, Aegerion, Amarin, BristolMeyersSquibb, Abbott, Gilead, ACC, Pfizer, Merck Kim Hustler: No Disclosures Session Objectives Outline the data points that will be changing for ACTION Registry GWTG Version 2.4 Discuss the rationale and implications for the changes in the data elements 1

Disclosures Dr. Joanne Foody No Disclosures to report Kim Hustler No Disclosures to report Version 2.4 Update - Why Change? New therapies/medications Research/Clinical Guidelines Collaborative/Integrated Care Improved quality of data in registry Public reporting Physician reporting Aligning with other NCDR Registries ARS Question #1 Who did we include in the process of determining what fields to add? 1. Email suggestions 2. RSM calls 3. Focused RSM teleconferences 4. Physician committee meetings 5. All of the above 2

ARS Question #2 How did we determine what fields to remove? 1. Frequency of fields being answered 2. Current practice 3. Core data elements 4. Enough data already captured 5. All of the above ACTION -GWTG Q.I. Subcommittee Members Dr. Joanne Foody Chair Dr. Karen Alexander Dr. Donald Casey Dr. Shahriar Dadkhah Dr William French Dr. Michael Ho Dr. Mauro Moscucci Dr. Gregg Fonarow Dr. Judith Lichtman Dr. Nurcan Illksoy Dr. James Jollis Dr. Mikhail Kosiborod Process SQOC Science & Quality Oversight Committee ACTION Registry GWTG Steering Committee Stakeholder feedback NCDR Management Board 3

Registry Site Manager Calls Calls were specifically to obtain feedback from users Two Teleconferences September 27, 2011 October 6, 2011 Be Careful What You Ask For! New therapies/medications Medications Dabigatran Rivaroxaban Apixaban Statin therapy at discharge, new fields Hypothermia Protocol 4

Section E- Medications New medication: Xarelto (Rivaroxaban) Documentation: History of Atrial fibrillation Presents with symptoms of ACS Positive Troponins- NSTEMI Physician discharges patient on Xarelto ARS Question # 32 How will you enter the Xarelto in the data collection tool? 1.Do not include 2.Answer Warfarin at discharge Seq. #6220 as contraindicated 3.Answer Warfarin at discharge Seq. #6220 as yes 5

Removed fields ASA date/time & dose (1 st 24 hours) Ticlopidine date/time & dose (1 st 24 hours) Prasugrel dose (1 st 24 hours) Beta blocker date/time Duration of P2Y12 s at discharge Option of blinded Version 2.4 6

New field for Statin therapy at discharge Less than Intensive Statin Therapy Intensive Statin Therapy Unfractionated Heparin GP IIB/IIIA Inhibitors 7

Anticoagulants removed Section E- Medications Excessive dosing UFH- no PCI Documentation: Presents with N/V, left arm pain 12 lead ECG- STEMI To cath lab for primary PCI- 5000 units UFH given in cath lab Coronary arteries- clean No PCI is performed Excessive dosing UFH- no PCI The data collection form would be completed as: Reperfusion Candidate #8000 yes Primary PCI #8015 no Reason no PCI #8030- Anatomy not suitable to primary PCI Thrombolytic no, reason #8035- Expected DTB <90 min- if was expected 8

ARS Question # 4 Would this patient be included in the UFH Excessive dosing report as we are currently entering it? 1. No 2. Yes Answer: #1 (No) As of October 1, 2013 discharges Diagnostic Angiography Time Seq. #7022 is the identifying time for UFH doses administered in the cath lab If date/time of UFH Seq. #6852/6853 is prior to Angiography time, it is included If after Angiography time- dose is excluded Documentation: Section E- Medications Excessive dosing UFH Presents with N/V, left arm pain at 04:00 12 lead ECG- negative Cardiac Biomarkers elevated- NSTEMI Weight 100 kg ED starts UFH infusion at 1000 U at 05:00 To cath lab at 08:00 5000 U IV bolus in cath lab administered at 08:15 9

ARS Question # 5 Would this patient be included in the UFH Excessive dosing report as we are currently entering it? 1. No 2. Yes V2.4 Excessive dose UFH V2.4 will capture date/time for both initial doses (bolus & infusion) The dates/times provide verification of administration prior to or after arrival in cath lab Patient can only fail the Excessive Dosing metric once Aligning Registries PCI Indications Arterial access site Demographics/Race Fields Mobile ICU 10

Version 2.3 Procedure fields Coronary Stenosis % removed Version 2.4 Procedures and Tests 11

PCI Indications & arterial access site Hypothermia therapy Section F- Procedures & Tests PCI Indication V2.4 Documentation: Presents with N/V & chest pressure Chest pressure started 2 days ago Vomiting started at 08:00, worsening CP ECG- ST elevation Emergently to cath lab at 09:45 12

ARS Question # 62 What would you select for PCI Indication? 1. Primary PCI for STEMI 2. PCI for STEMI (unstable, >12 hr from sx onset) 3. PCI for STEMI (stable,, >12 hr from sx onset) Version 2.4 Additions Demographics- Race detail lines Section A- Demographics Hispanic or Latino Ethnicity Documentation: Presents meeting criteria for NSTEMI Noted in town visiting family, home Mexico Her last name is Garcia Primary language: English Secondary language: Spanish No documentation of race/ethnicity in medical record 13

ARS Question #72 How would you answer Hispanic or Latino Ethnicity Seq. #2076? 1. No 2. Yes 3. Yes, Mexican Research/Clinical Guidelines Additional In-Hospital Clinical events Home Functioning/Cognitive Status In-Hospital Clinical Events 14

Home Functioning Cocaine use COPD Atrial fib or flutter- past 2 weeks removed Cancer history added Detail under Cerebrovascular disease 15

Collaborative/Integrated Care Two FMC fields to capture non-ems FMC Non-system reason for delay for First Medical Contact Additional EMS fields & cath lab activation for FMC Two FMC fields to capture non-ems FMC Non-system reason for delay for First Medical Contact Section B- Admission Means of Transport to First Facility Documentation: EMS called to home of female with symptoms of ACS BLS unit dispatched, ALS unit arrived 5 minutes later 12 Lead ECG read- ST elevation ASA is administered ECG reading phoned into ED ALS unit transported to primary PCI hospital 16

ARS Question # 8 What would you enter for Means of Transport to First Facility? 1. Self/Family 2. Ambulance 3. Mobile ICU Section B- Admission First Medical Contact time Seq. #3106 Documentation: Presented to physician office at 11:30 with 2 hours of epigastric pain, and pain radiating down left arm ECG- STEMI EMS patient contact time 11:50- transported by ambulance to PCI hospital Immediate Primary PCI ARS Question # 9 What time would you enter in for First Medical Contact time Seq. #3106? 1. 11:30 Physician Office contact time 2. 11:50 EMS contact time 3. Leave time blank 17

Data Collection Form Starting with January 1, 2014 discharges Enter into Auxiliary field 4 the response to question: Was EMS the first medical contact? Data Collection Tool Enter Y or N into Auxiliary field 4 under Discharge Note- answer N when no first medical contact Additional EMS fields & cath lab activation 18

Improved quality of data in registry Non-system reason for delay for ECG s Geographic concerns with D 2 B patients Initial and peak lab values Non-system reason for delay for ECG s V2.4 Changes Door to ECG Quality Metric #22 Documentation: EMS arrives at scene patient in cardiac arrest Code ran 11 minutes- Defib, CPR, medsresuscitated Transported to hospital- presented in cardiac arrest at 11:05 Coded for 10 minutes-resuscitated ECG- at 11:20- STEMI Immediate Primary PCI 19

ARS Question # 10 How is the ECG captured currently? 1. 1 st ECG in metric denominator/ no numerator 2. Subsequent ECG- excluded 3. Excluded for non-system reason for delay Geographic concerns with D 2 B patients Initial & peak or lowest lab values same - check box 20

Troponin & CK-MB initial and peak date/time fields removed Public reporting/ Core Measures LVEF measured after discharge Public reporting Physician Provider Number (NPI) Admitting Procedure Discharge 21

Physician Level Dashboard Reporting Physician Quality Reporting System (PQRS) Reimbursement Promotes reporting of quality information by eligible providers Providers identified by NPI # Limited and Premier Forms- Current 140 fields in Limited vs. 280 fields in Premier Simple/Avg pt = 60-80 fields vs. 100-150 in Premier Complicated pt = 80-100 fields vs. 150-200 in Premier Non PCI centers 60 fields vs. 100 in Premier Strongly encourage participants to use Premier data set, especially P-PCI capable centers 22

Limited and Premier Forms- V 2.4 160 fields in Limited vs. 260 fields in Premier Addition of fields in Limited include: EMS fields (Mission Lifeline reporting) Reasons for no Reperfusion Location of First Evaluation Value out of range for LDL Limited and Premier Forms V2.4 25% fewer date/time fields Set to no functionality in ACC data collection tool Limited and Premier Forms V2.4 Limited form answering no to many parent fields will close child fields As few as 75 fields for Limited, 120 for Premier Referring hospitals can review their performance on care measures provided 23

Contact NCDR for questions at ncdr@acc.org or call 800-257 257-4737 24